TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

12.02.2022

To,
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Outcome of Board Meeting in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In continuation of our Letter dated 02th February, 2022 we wish to inform you that a meeting of the Board of Directors of the Company was held on **Saturday, 12th February, 2022**at **A 601, Floor No.6, Kailash Business Park, Veer Savarkar Marg, Vikroli - West, Mumbai – 400079 at 3.00 p.m.**and has transacted the following:-

1. Considered and approvedUn-Audited Financial Results (Standalone & Consolidated) for the quarterended on 31th December, 2021 and took note of Limited Review Report thereon, in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015;

The meeting of Board of Directors commenced at 3.00 p.m. and concluded at 5.00 p.m.

This is for your information and record.

Thanking you.
For Tejnaksh Healthcare Limited

Tejnaksh Healthcare Limited MUMBAI

Dr. Ashish V. Rawandale
Managing Director
DIN:- 02005733

Independent Auditor's Review Report on quarterly and year to date unaudited Standalone Ind AS Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Tejnaksh Healthcare Limited ("the Company") for the quarter ended December 31,2021 and year to date from April 01, 2021 to December 31, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accow1tants of India. This standard requires that we plan and perfom1 the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P.D.Dalal & Co.
Chartered Accountants
ICAI Firm Reg No.102047W
Akakaria

(Aashish S. Kakaria)
Partner
Membership No.102915
UDIN: 22102915ABNPFD2986

P.D.DALAL & CO. Chartered Accountants

Mumbai
12th February, 2022

TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER, 2021

Sl.No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		December 31,2021	September 30,2021	December 31,2020	December 31,2021	December 31,2020	March 31,2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**REVENUE**						
(a)	Revenue from operations (net)	194.74	207.66	249.86	635.84	637.15	855.81
(b)	Other income	3.77	1.04	0.86	7.83	4.29	15.35
	Total Revenue (I)	198.51	208.70	250.72	643.66	641.44	871.15
2	**EXPENSES**						
(a)	Purchases of stock-in-trade	21.15	16.56	7.64	63.19	26.69	52.67
(b)	Changes in inventories of Stock-in-Trade	(3.27)	(6.16)	3.64	(4.45)	(7.54)	(8.07)
(c)	Employee benefits expense	18.86	15.80	27.66	52.42	71.67	91.53
(d)	Finance costs	9.70	10.80	12.09	28.24	41.63	53.63
(e)	Depreciation and amortization expense	14.19	14.36	15.85	42.76	46.54	61.19
(f)	Other expenses	56.39	61.37	116.10	182.29	283.44	361.19
	Total Expenses (II)	117.03	112.72	182.98	364.45	462.43	612.14
3	**Profit before tax (I) - (II)**	81.48	95.98	67.75	279.21	179.01	259.01
4	**Tax expense:**						
(a)	Current tax	18.80	22.70	11.55	65.05	36.62	57.27
(b)	Deferred tax	1.71	1.68	(4.41)	5.23	1.48	1.32
	Total Tax Expenses	20.51	24.38	7.14	70.28	38.10	58.59
5	**Profit for the Period**	60.97	71.60	60.61	208.94	140.91	200.42
6	**OTHER COMPREHENSIVE INCOME**						
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:						
	Actuarial gain / (loss) on liabilities	0.33	0.66	-	0.99	-	1.32
	Income tax effect	(0.08)	(0.17)	-	(0.25)	-	(0.33)
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:	-	-	-	-	-	-
	Other Comprehensive income for the period, net of tax	0.25	0.49	-	0.74	-	0.99
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	61.22	72.10	60.61	209.68	140.91	201.40
7	**Paid up Equity Share Capital (Face value Rs 10/- each.)**	101.57	101.57	101.57	101.57	101.57	101.57
8	**Basic and Diluted earnings per share (INR)**	0.60	0.70	0.60	2.06	1.39	1.97

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

Notes:

1) The Statement of unaudited standalone financial results ('the Statement') of Tejnaksh Healthcare Ltd. ('the Company') for the quarter and nine months ended December 31, 2021 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on February 12, 2022. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.

2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3) The Company has only one reportable primary business segment as per IND AS 108 - "Operating Segments" i.e 'Medical and Healthcare Services. Since the Company has a single operating segment disclosure pertaining to segments is not applicable.

4) The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company's operations and revenue during the period were impacted due to COVID-19. However, it has no further significant impact with respect to COVID 19 pandemic during the quarter and nine month ended December 31, 2021.

5) The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.

6) There were no investor complaints received / pending as at 31st December, 2021.

For and on behalf of board of Directors
Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)
Managing Director
DIN: 02005733

Mumbai
February 12, 2022

Tejnaksh Healthcare Limited MUMBAI

Independent Auditor's Limited Review Report on quarterly and year to date unaudited Consolidated Ind AS Financial Results pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Tejnaksh Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended December 31,2021 and year to date from April 01, 2021 to December 31, 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2.This Statement, which is the responsibility of the Parent's Management and approved by the Parents Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (Ind AS 34) 'Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3.We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410. Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and performthe review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial infom1ation consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4.The Statement includes results of the Holding Company- Tejnaksh Healthcare Limited and subsidiary Company - Tej Vedaant Healthcare Private Limited.

5.The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its subsidiary which have been approved and furnished to us by the management. Our conclusion on the Statement is not modified in respect of the above matter.

P. D. DALAL & CO. Chartered Accountants

102, B Wing, Lake Florence, Phase I, Adi Shankaracharya Marg, Powai,
Mumbai - 400 076 Maharashtra India Email : auditpdd@gmail.com

6. Based on our review conducted and procedures performed as stated in paragraph 3 above,nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed. or that it contains any material misstatement.

For P.D.Dalal & Co.
Chartered Accountants
ICAI Firm Reg. No.102047W

(Aashish S. Kakaria)
Partner
Membership No.102915
UDIN: 22102915ABNTLU8333

Mumbai
12th February, 2022

TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER, 2021

Sl.No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		December 31,2021	September 30,2021	December 31,2020	December 31,2021	December 31,2020	March 31,2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**REVENUE**						
(a)	Revenue from operations (net)	308.02	344.35	342.16	973.51	834.93	1,196.01
(b)	Other income	3.83	1.22	0.01	8.64	1.98	13.85
	Total Revenue (I)	**311.84**	**345.57**	**342.17**	**982.15**	**836.91**	**1,209.86**
2	**EXPENSES**						
(a)	Purchases of stock-in-trade	36.12	36.69	21.50	110.63	57.23	95.67
(b)	Changes in inventories of Stock-in-Trade	(8.38)	(0.21)	6.31	1.06	(6.17)	(6.17)
(c)	Employee benefits expense	33.76	33.22	40.22	100.24	101.16	138.75
(d)	Finance costs	9.70	10.80	11.24	28.24	39.06	50.21
(e)	Depreciation and amortization expense	16.20	16.07	17.56	48.15	51.69	68.05
(f)	Other expenses	127.72	148.61	177.06	395.54	434.98	596.53
	Total Expenses (II)	**215.12**	**245.17**	**273.89**	**683.86**	**677.95**	**943.05**
3	**Profit before tax (I) - (II)**	**96.72**	**100.40**	**68.28**	**298.29**	**158.96**	**266.80**
4	**Tax expense:**						
(a)	Current tax	22.26	24.00	11.55	69.82	36.62	59.15
(b)	Deferred tax	2.08	1.36	(4.75)	5.26	1.04	0.73
	Total Tax Expenses	24.34	25.37	6.80	75.08	37.66	59.88
5	**Profit for the year**	72.38	75.04	61.48	223.22	121.30	206.92
6	**OTHER COMPREHENSIVE INCOME**						
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:						
	Actuarial gain / (loss) on liabilities	0.35	0.71	-	1.06	-	1.42
	Income tax effect	(0.09)	(0.18)	-	(0.27)	-	(0.36)
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:	-	-	-	-	-	-
	Other Comprehensive income for the year, net of tax	0.26	0.53	-	0.80	-	1.06
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	72.64	75.57	61.48	224.01	121.30	207.99
7	**Profit for the year attributable to:**						
	Equity holders of the parent	68.29	73.96	61.26	218.20	126.20	205.30
	Non-controlling interests	4.08	1.07	0.22	5.01	(4.90)	1.63
8	**Other comprehensive income for the year attributable to:**						
	Equity holders of the parent	0.26	0.52	-	0.78	-	1.04
	Non-controlling interests	0.00	0.01	-	0.01	-	0.02

Tejnaksh Healthcare Limited MUMBAI

TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

9	**Total comprehensive income for the year attributable to:**						
	Equity holders of the parent	68.55	74.49	61.26	218.98	126.20	206.34
	Non-controlling interests	4.09	1.08	0.22	5.03	(4.90)	1.65
10	**Paid up Equity Share Capital (Face value Rs 10/- each.)**	101.57	101.57	101.57	101.57	101.57	101.57
11	**Basic and Diluted earnings per share (INR)**	0.67	0.73	0.60	2.15	1.24	2.02

Notes:

1) The Statement of unaudited consolidated financial results ('the Statement') of Tejnaksh Healthcare (the'Parent'/ 'Group') and its subsidiaries (together referred to as the 'Group') for the quarter/nine months ended December 31, 2021 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on February 12, 2022. The Statutory Auditors of the Group have carried out a Limited Review of the aforesaid results.

2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3) The Group's has only one reportable primary business segment as per IND AS 108 - "Operating Segments" i.e 'Medical and Healthcare Services. Since the Company has a single operating segment disclosure pertaining to segments is not applicable.

4) The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Group's operations and revenue during the period were impacted due to COVID-19. However, it has no further significant impact with respect to COVID 19 pandemic during the quarter and nine months ended December 31, 2021.

5) The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.

6) There were no investor complaints received / pending as at 31st December, 2021.

For and on behalf of board of Directors
Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)
Managing Director
DIN: 02005733

Tejnaksh Healthcare Limited MUMBAI

Mumbai
February 12, 2022